Stephanie A Sweetana from 11502 Woodview East Dr E, Carmel, IN 46032, age 63, Phone: 317 372-5974

Echinocandin Pharmaceutical Formulations Containing Micelle-Forming Surfactants
view source
US Patent:

6960564, Nov 1, 2005
Filed:

Aug 29, 2001
Appl. No.:

09/942431
Inventors:

Nathaniel Milton - Indianapolis IN, US
Kenneth Philip Moder - West Lafayette IN, US
James Lawrence Sabatowski - Holland MI, US
Stephanie Ann Sweetana - Bloomington IN, US
Assignee:

Eli Lilly and Company - Indianapolis IN
International Classification:

A61K038/12
US Classification:

514 11, 530317, 424400, 424489
Abstract:

Pharmaceutical formulations are described comprising an echinocandin compound or echinocandin/carbohydrate complex and a pharmaceutically acceptable micelle-forming surfactant in a non-toxic aqueous solvent such that the solubilization of the echinocandin compound is optimized and the ability to freeze-dry the solution is maintained. Both the solution and freeze-dried formulations have increased stability. A bulking agent, tonicity agent buffer and/or a stabilizing agent may optionally be added to the formulations to further enhance the stability of the formulation.

Prodrugs Of Excitatory Amino Acids
view source
US Patent:

7038077, May 2, 2006
Filed:

Jan 9, 2002
Appl. No.:

10/465972
Inventors:

Anne Hollins Dantzig - Crawfordsville IN, US
James Allen Monn - Indianapolis IN, US
Stephanie Ann Sweetana - Carmel IN, US
Ana Belen Bueno Melendo - Madrid, ES
Alfonso De Dios - Madrid, ES
Carmen Dominguez-Fernandez - Madrid, ES
Marc Francis Herin - Perwez, BE
Luisa Maria Martin-Cabrejas - Madrid, ES
Jose Alfredo Martin - Madrid, ES
Maria Angeles Martinez-Grau - Madrid, ES
Carlos Montero Salgado - Madrid, ES
Concepcion Pedregal-Tercero - Madrid, ES
Assignee:

Eli Lilly and Company - Indianapolis IN
International Classification:

C07C 61/12
US Classification:

562501, 562502
Abstract:

This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.

Echinocandin Pharmaceutical Formulations Containing Micelle-Forming Surfactants
view source
US Patent:

7709444, May 4, 2010
Filed:

Apr 11, 2005
Appl. No.:

11/103798
Inventors:

Nathaniel Milton - Indianapolis IN, US
Kenneth Philip Moder - West Lafayette IN, US
James Lawrence Sabatowski - Holland MI, US
Stephanie Ann Sweetana - Bloomington IN, US
Assignee:

Pfizer Inc. - New York NY
International Classification:

A61K 38/12
US Classification:

514 11, 530317, 424400, 424489
Abstract:

Pharmaceutical formulations are described comprising an echinocandin compound or echinocandin/carbohydrate complex and a pharmaceutically acceptable micelle-forming surfactant in a non-toxic aqueous solvent such that the solubilization of the echinocandin compound is optimized and the ability to freeze-dry the solution is maintained. Both the solution and freeze-dried formulations have increased stability. A bulking agent, tonicity agent buffer and/or a stabilizing agent may optionally be added to the formulations to further enhance the stability of the formulation.

Solid Orally Administerable Raloxifene Hydrochloride Pharmaceutical Formulation
view source
US Patent:

59723831, Oct 26, 1999
Filed:

Jun 1, 1998
Appl. No.:

9/088695
Inventors:

Lowell L. Gibson - Greenwood IN
Kerry J. Hartauer - Indianapolis IN
Julian L. Stowers - Indianapolis IN
Stephanie A. Sweetana - Bloomington IN
Arvind L. Thakkar - Indianapolis IN
Assignee:

Eli Lilly and Company - Indianapolis IN
International Classification:

A61K 920
A61K 31445
US Classification:

424464
Abstract:

This invention provides orally administerable pharmaceutical formulations comprising raloxifene, its ethers or esters, or a pharmaceutically-acceptable salt thereof, in combination with a hydrophilic carrier composition.

Solid Orally Administerable Raloxifene Hydrochloride Pharmaceutical Formulation
view source
US Patent:

58111204, Sep 22, 1998
Filed:

Mar 26, 1997
Appl. No.:

8/824590
Inventors:

Lowell L. Gibson - Greenwood IN
Kerry J. Hartauer - Indianapolis IN
Julian L. Stowers - Indianapolis IN
Stephanie A. Sweetana - Bloomington IN
Arvind L. Thakkar - Indianapolis IN
Assignee:

Eli Lilly and Company - Indianapolis IN
International Classification:

A61K 920
A61K 31445
US Classification:

424464
Abstract:

This invention provides solid orally administerable pharmaceutical formulations comprising raloxifene hydrochloride, a surfactant being sorbitan fatty acid ester or a polyoxyethylene sorbitan fatty acid ester, polyvinylpyrrolidone, and a water soluble diluent which is polyol or sugar.

Aqueous Solution Inclusion Complexes Of Benzothiophene Compounds With Water Soluble Cyclodextrins, And Pharmaceutical Formulations And Methods Thereof
view source
US Patent:

56249403, Apr 29, 1997
Filed:

Jun 30, 1995
Appl. No.:

8/497327
Inventors:

Henry U. Bryant - Indianapolis IN
George J. Cullinan - Trafalgar IN
Paul C. Francis - Indianapolis IN
David E. Magee - Indianapolis IN
Stephanie A. Sweetana - Bloomington IN
Arvind L. Thakkar - Indianapolis IN
Assignee:

Eli Lilly and Company - Indianapolis IN
International Classification:

A61K 3140
A61K 31445
A61K 4740
US Classification:

514324
Abstract:

The present invention provides aqueous inclusion complexes of certain known benzothiophene compounds, particularly Raloxifene, and water soluble cyclodextrins. Also provided are pharmaceutical compositions of such inclusion complexes, and methods of using these complexes for inhibiting bone loss and reducing serum cholesterol in mammals.

Polypeptide Composition For Oral Administration
view source
US Patent:

61567310, Dec 5, 2000
Filed:

Dec 5, 1995
Appl. No.:

8/567501
Inventors:

George M. Grass - Mountain View CA
Stephanie A. Sweetana - Indianapolis IN
Assignee:

G. D. Searle & Co. - Skokie IL
International Classification:

A61K 3800
A61K 3900
C07K 500
C07K 700
US Classification:

514 15
Abstract:

There is disclosed a composition containing a biologically active polypeptide selected from LHRH, an LHRH analog, somatostatin and a somatostatin analog, in a therapeutically effective amount, a membrane permeability enhancing agent, and a protease enzyme inhibitor enveloped within an enteric coating. The composition possesses enhanced bioavailability upon oral administration.

Topical Formulations
view source
US Patent:

20180256570, Sep 13, 2018
Filed:

Nov 28, 2016
Appl. No.:

15/779480
Inventors:

- San Diego CA, US
Stephanie Ann SWEETANA - Indianapolis IN, US
Assignee:

IGNYTA, INC. - San Diego CA
International Classification:

A61K 31/502
A61K 47/38
A61K 47/20
A61K 47/10
A61K 9/00
A61P 35/00
Abstract:

Described herein are pharmaceutical formulations comprising 4-fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical formulations are suitable for topical use, and methods of using such formulations in the treatment of subjects having cancer.

Stephanie A Sweetana